Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dose-effect and structure-function relationships in doxorubicin cardiomyopathy

M R Bristow, J W Mason, M E Billingham

    American Heart Journal
    |October 1, 1981
    PubMed
    Summary

    Doxorubicin (DXR) chemotherapy causes dose-dependent heart damage (cardiomyopathy). Heart function declines sharply only after a critical level of damage is reached, revealing a threshold effect in DXR-induced cardiac toxicity.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Comparison of PR, QRS, and QT interval measurements by seven ECG interpretation programs.

    Journal of electrocardiology·2020
    Same author

    Tobacco.

    The American journal of dental science·2019
    Same author

    Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial.

    Clinical pharmacology and therapeutics·2015
    Same author

    Lacosamide cardiac safety: clinical trials in patients with partial-onset seizures.

    Acta neurologica Scandinavica·2015
    Same author

    Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil.

    Clinical pharmacology and therapeutics·2014
    Same author

    Collagenolytic activity of synovium in rheumatoid arthritis.

    The New England journal of medicine·2010

    Area of Science:

    • Cardiology
    • Oncology
    • Pharmacology

    Background:

    • Doxorubicin (DXR) is a potent anticancer agent.
    • DXR can induce cardiotoxicity, leading to cardiomyopathy (CM).
    • Understanding DXR-induced CM is crucial for managing cancer patients.

    Purpose of the Study:

    • To investigate the dose-effect and structure-function relationships in DXR-induced cardiomyopathy.
    • To correlate morphologic damage with functional performance abnormalities.

    Main Methods:

    • Ultrastructural examination of endomyocardial biopsies to assess morphologic damage.
    • Right heart catheterization to evaluate cardiac performance abnormalities.
    • Analysis of correlations between DXR cumulative dose, morphologic damage, and cardiac function.

    Related Experiment Videos

    Main Results:

    • Morphologic damage was proportional to the cumulative DXR dose (100–600 mg/m²).
    • Cardiac performance abnormalities showed a weak, curvilinear relationship with dose, with a threshold for expression.
    • Catheterization abnormalities correlated well with morphologic damage (r = 0.57 to 0.78), also exhibiting a threshold configuration.

    Conclusions:

    • Myocardial damage from DXR is directly proportional to the cytotoxic dose.
    • Cardiac function is preserved until a critical threshold of damage is reached.
    • Beyond this threshold, myocardial performance deteriorates rapidly in DXR-induced cardiomyopathy.